Leap Therapeutics (NASDAQ:LPTX) lost 63% in the premarket on Tuesday after the antibody-based drug developer announced that it would not advance its lead candidate, sirexatamab, in Phase 3 studies ...
Hosted on MSN28d
Leap Therapeutics stock hits 52-week low at $0.8Leap Therapeutics Inc . (NASDAQ:LPTX) shares have tumbled to a 52-week low, touching down at $0.8 amidst a challenging market environment. With a market capitalization of just $29.89 million ...
Additional updates on the progression free survival data provide a future catalyst, with LPTX planning to provide updates in 2025. LPTX plans to run a phase 3 study of DKN-01 in colorectal cancer ...
Leap Therapeutics (NASDAQ:LPTX) fell ~12% on Wednesday as Baird downgraded the stock after the biotech said its lead candidate, sirexatamab, generated disappointing data in a mid-stage trial for ...
NASDAQ LPTX opened at $0.56 on Thursday. The company has a market capitalization of $21.46 million, a PE ratio of -0.29 and a beta of 0.17. Leap Therapeutics has a twelve month low of $0.51 and a ...
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes Leap Therapeutics' Phase 2 data shows sirexatamab improves ORR in colorectal cancer ...
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback